Monday, September 26, 2022 3:10:59 PM
One last dance?
Recent BIIB News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 10:11:26 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 04/06/2026 10:08:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 10:31:37 AM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 04/03/2026 09:10:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 09:03:19 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 03/31/2026 09:01:35 PM
- Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology • GlobeNewswire Inc. • 03/31/2026 10:59:00 AM
- Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology • GlobeNewswire Inc. • 03/31/2026 10:59:00 AM
- FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity • GlobeNewswire Inc. • 03/28/2026 07:00:00 PM
- Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026 • PR Newswire (US) • 03/20/2026 04:05:00 PM
- Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Biogen shares Phase 1b findings for salanersen in spinal muscular atrophy • IH Market News • 03/11/2026 03:09:29 PM
- Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy • GlobeNewswire Inc. • 03/11/2026 12:00:00 PM
- Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences • GlobeNewswire Inc. • 03/05/2026 12:30:00 PM
- The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome • GlobeNewswire Inc. • 03/04/2026 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:18:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:17:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:16:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:12:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:11:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:10:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:09:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:07:57 AM
